Abstract:Ferroptosis is a form of lipid peroxidation-mediated cell death and damage triggered by excess iron and insufficiency in the glutathione antioxidant pathway. Oxidative stress is thought to play a crucial role in progressive forms of multiple sclerosis (MS) in which iron deposition occurs. In this study we assessed if ferroptosis plays a role in a chronic form of experimental autoimmune encephalomyelitis (CH-EAE), a mouse model used to study MS. Changes were detected in the mRNA levels of several ferroptosis genes in CH-EAE but not in relapsing–remitting EAE. At the protein level, expression of iron importers is increased in the earlier stages of CH-EAE (onset and peak). While expression of hemoxygenase-1, which mobilizes iron from heme, likely from phagocytosed material, is increased in macrophages at the peak and progressive stages. Excess iron in cells is stored safely in ferritin, which increases with disease progression. Harmful, redox active iron is released from ferritin when shuttled to autophagosomes by 'nuclear receptor coactivator 4' (NCOA4). NCOA4 expression increases at the peak and progressive stages of CH-EAE and accompanied by increase in redox active ferrous iron. These changes occur in parallel with reduction in the antioxidant pathway (system xCT, glutathione peroxidase 4 and glutathione), and accompanied by increased lipid peroxidation. Mice treated with a ferroptosis inhibitor for 2 weeks starting at the peak of CH-EAE paralysis, show significant improvements in function and pathology. Autopsy samples of tissue sections of secondary progressive MS (SPMS) showed NCOA4 expression in macrophages and oligodendrocytes along the rim of mixed active/inactive lesions, where ferritin+ and iron containing cells are located. Cells expressing NCOA4 express less ferritin, suggesting ferritin degradation and release of redox active iron, as indicated by increased lipid peroxidation. These data suggest that ferroptosis is likely to contribute to pathogenesis in CH-EAE and SPMS.

Ferroptosis Promotes T-cell Activation-Induced Neurodegeneration in Multiple Sclerosis.

Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease progression

Insight into the Role of Ferroptosis in Non-neoplastic Neurological Diseases

Ferroptosis as a mechanism of oligodendrocyte loss and demyelination in experimental autoimmune encephalomyelitis

Ferroptosis induces detrimental effects in chronic EAE and its implications for progressive MS

Targeting ferroptosis in neuroimmune and neurodegenerative disorders for the development of novel therapeutics

Mechanisms of Ferroptosis and Emerging Links to the Pathology of Neurodegenerative Diseases

Role of ferroptosis in neuroimmunity and neurodegeneration in multiple sclerosis revealed by multi‐omics data

Research on Ferroptosis as a Therapeutic Target for the Treatment of Neurodegenerative Diseases

Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis

Targeting Ferroptosis for Cancer Therapy: Exploring Novel Strategies from Its Mechanisms and Role in Cancers

Targeted RNAseq Revealed the Gene Expression Signature of Ferroptosis-Related Processes Associated with Disease Severity in Patients with Multiple Sclerosis

Ferroptosis participates in neuron damage in experimental cerebral malaria and is partially induced by activated CD8+ T cells

The Role of Ferroptosis in Amyotrophic Lateral Sclerosis Treatment

Ferroptosis-Regulated Cell Death As a Therapeutic Strategy for Neurodegenerative Diseases: Current Status and Future Prospects

Ferroptosis Mediated by Lipid Reactive Oxygen Species: A Possible Causal Link of Neuroinflammation to Neurological Disorders

Microglia ferroptosis is prevalent in neurodegenerative disease and regulated by SEC24B

Insight into the potential role of ferroptosis in neurodegenerative diseases

Establishment of the Diagnostic Signature of Ferroptosis Genes in Multiple Sclerosis

Ferroptosis and Its Potential Role in the Nervous System Diseases

Targeting ferroptosis in autoimmune diseases: Mechanisms and therapeutic prospects